

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jeppesen et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: August 28, 2001

Examiner: To be assigned

For: Heterocyclic Compounds and their Preparation and Use



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants cite herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. **Copies of references were filed with USSN 09/148,637, the benefit of which is claimed under 35 USC 120.**

The references are as follows:


1. EP 0 709 381
2. EP 0 745 601
3. WO 92/03433
4. WO 95/17180

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on the filing date of the application. Therefore, no fee is due.

Respectfully submitted,

Date: 28 August 2001


Valeta A. Gregg, Reg. No. 55,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No.
4759.224-USSerial No.
to be assignedINFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant
Jeppesen et al.Filing Date
August 28, 2001Group
to be assigned

(Use several sheets if necessary)

JC971 U.S. PTO
09/940963

08/28/01

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 709 381	5/1/96	EPO				
	EP 0 745 601	12/4/96	EPO				
	WO 92/03433	3/5/92	PCT				
	WO 95/17180	6/29/95	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.